POLA Orbis Holdings

POLA Orbis Holdings is a prominent Japanese beauty and health conglomerate specializing in high-performance skincare, cosmetics, and dermatological research. The company is distinguished by its robust R&D capabilities, particularly through Pola Chemical Industries, which focuses on developing proprietary active ingredients for the Japanese "quasi-drug" market. Its flagship brands, POLA and ORBIS, are supported by a portfolio of international and niche brands such as Jurlique and THREE. POLA Orbis is a pioneer in anti-aging and skin-brightening science, having launched the first quasi-drug in Japan clinically proven to improve wrinkles. The group maintains a vertically integrated business model, encompassing basic research, formulation, manufacturing, and multi-channel distribution. While it sold its dedicated pharmaceutical subsidiary in 2019, it continues to leverage medical-grade science to drive innovation in the global prestige beauty and wellness sectors.